| Alternative Name: | Glycogen synthase kinase-3β |
| |
| Host: | Rabbit |
| |
| Immunogen: | Synthetic peptide corresponding to a portion of rat GSK-3β. The sequence is completely conserved in human. |
| |
| UniProt ID: | P18266 |
| |
| GenBank ID: | X53428 |
| |
| Source: | Purified from rabbit serum. |
| |
| Species reactivity: | Human, Mouse, Rat
Bovine
|
| |
| Applications: | ICC, IHC (PS), WB
|
| |
| Recommended Dilutions/Conditions: | Western Blot (1:1,000, colorimetric)
Suggested dilutions/conditions may not be available for all applications.
Optimal conditions must be determined individually for each application. |
| |
| Application Notes: | Detects a band of ~47kDa by Western blot. |
| |
| Purity Detail: | Protein A affinity purified. |
| |
| Formulation: | Liquid. In PBS, pH 7.2, containing 50% glycerol and 0.09% sodium azide. |
| |
| Handling: | Avoid freeze/thaw cycles. |
| |
| Shipping: | Blue Ice |
| |
| Long Term Storage: | -20°C |
| |
| Scientific Background: | Glycogen Synthase Kinase 3β (GSK-3β) is a unique serine/threonine kinase that is inactivated by phosphorylation. In response to insulin binding, PKB/AKT phosphorylates GSK-3β on serine 9, which prevents GSK-3β from phosphorylating glycogen synthase. Unphosphorylated glycogen synthase is active and able to synthesize glycogen. GSK-3β is also unique in that it requires a substrate that has been phosphorylated by a distinct kinase before it can phosphorylate the substrate. This phosphate priming mechanism explains why phosphorylation of serine 9 inactivates GSK-3β. The phosphorylated serine binds to the GSK-3β priming phosphate position and prevents binding of alternative substrates. In addition to insulin signaling, GSK-3β participates in the Wnt signaling pathway, where it forms a complex with axin, beta-catenin and adenomatous polyposis coli (APC) protein. In the presence of Wnts, GSK-3β is unable to phosphorylate beta-catenin, which leads to stabilization of beta-catenin. The Wnt pathway inactivates GSK-3β via the proteins, Dishevelled and FRAT, which disrupt the interaction of GSK-3β with axin, beta-catenin, and APC. Clinically, there is considerable interest in GSK-3β inhibitors because they may mimic the effect of insulin or reduce the hyperphosphorylation of Tau that is observed in Alzheimer's Disease. |
| |
| Regulatory Status: | RUO - Research Use Only |
| |
